Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WEST LAFAYETTE, Ind., Aug. 27, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
-
WEST LAFAYETTE, Ind., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
-
WEST LAFAYETTE, Ind., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
-
WEST LAFAYETTE, Ind., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for...
-
– EC1456 Targeting Potent Tubulysin Payload to Advance in Phase 1 to Dose Similar to Vintafolide – – Conference Call Today at 4:30 p.m. EDT – WEST LAFAYETTE, Ind., July...
-
WEST LAFAYETTE, Ind., July 22, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) announced today that the company will host a conference call on Tuesday, July 29, at 4:30 p.m. EDT to discuss its...
-
WEST LAFAYETTE, Ind., June 17, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc., (Nasdaq:ECYT) today announced that it has regained the worldwide rights to vintafolide in all indications from Merck, known as...
-
WEST LAFAYETTE, Ind., May 19, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion...
-
- Independent DSMB Recommends to Stop Phase 3 PROCEED Trial for Futility Following Interim Analysis – - Endocyte Initiates Phase 1 Trial of PSMA-Targeted Tubulysin SMDC (EC1169) in Prostate...
-
WEST LAFAYETTE, Ind., May 1, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized...